Some grasses are a sustainable energy source that could be a driving force towards achieving net zero carbon emissions, according to new research that demonstrates their resilience to harsh growing environments.
SHEFFIELD, England, April 20, 2021 /PRNewswire/ -- Rinri Therapeutics, a biotechnology company developing a novel stem cell therapy to restore hearing, today announces that it has raised a total of £10 million from existing investors Boehringer Ingelheim Venture Fund (BIVF), UCB Ventures and BioCity alongside the UK Government Future Fund. The proceeds will support the development of the Company's novel stem cell therapy to reverse sensorineural hearing loss (SNHL).
Today we have published our latest quarterly update which gives an overview of key policy developments and the BIA’s continued engagement with policymakers, regulatory authorities and wider stakeholders on behalf of the UK life sciences sector, from January to April 2021.
Laval, Quebec, March 23, 2021 – WCCT Global, an Altasciences company, announced the expansion of their clinical pharmacology unit and laboratory earlier this year. Today, Altasciences confirms the unit dosed its first study participants.
• Investment will accelerate the progression of the Company’s lead therapeutic antibody programme towards the clinic and further expand its internal product pipeline
• Latest financing takes total funds raised to $34 million
New incentives should be explored to encourage innovation in life sciences, especially in areas where the traditional model of incentives might not be working or sufficiently encouraging the development of medicines that society needs.
NORWICH, UK – 13 April 2021: HotHouse BioEngineering (HHBE), which was founded on a body of work from the laboratory of Professor Anne Osbourn FRS OBE of the John Innes Centre, and Leaf Expression Systems (Leaf), a contract development and manufacturing organisation specialising in plant-based expression and production of proteins, today announced a non-exclusive agreement granting HHBE use of Leaf’s expression technology, Hypertrans® for research and development.
We all know how important R&D tax credits are for the Life Sciences, Pharmaceuticals, and Biotech sectors. Most companies in these industries have been claiming since day one, and yet we often encounter companies who are significantly underclaiming. The average benefit for companies in these industries is just over £110k, but Ayming’s average claim for companies in these industries is currently more than £700k, so why is there such a discrepancy?
It was fantastic to see the launch of the Medicines & Diagnostics Manufacturing Transformation Fund which aims to boost economic opportunities, innovation and health resilience by supporting medicines and diagnostics manufacturing investments in the UK.
Medannex Ltd (Edinburgh) today announced the presentation of new data at the annual meeting of the
American Association for Cancer Research (AACR), highlighting the multi-faceted anti-cancer activity of
MDX-124 - the company’s proprietary therapeutic antibody.